The markets opened mixed with the Dow losing 30 points to 15,606 while Nasdaq added 4 points to 3793 as investors continued to mull over the Federal Reserve’s decision to delay tapering.
On the upside
JinkoSolar (NYSE: JKS) priced its follow-on public offering of 3.8 million American Depositary Shares at $16.25 per ADS.
Cyclacel Pharmaceuticals (Nasdaq: CYCC) reported that its sapacitabine showed promise in treating ovarian cancer.
BASF will pay a premium of approximately $51.2 million to acquire Verenium (Nasdaq: VRNM).
On the downside
Prosena (Nasdaq: RNA) and GlaxoSmithKline (NYSE: GSK) reported disappointing results from a Phase III clinical trial of its Duchenne Muscular Dystrophy treatment drisapersen.
AK Steel (NYSE: AKS) blamed an outage for forecasting a greater than expected loss for the third quarter.
Baltic Trading (NYSE: BALT) priced its public offering of 12 million common shares at the discounted price of $4.60 per share.
In the broad market, declining issues outpaced advancers by a margin of 5 to 3 on the NYSE and by more than 10 to 9 on Nasdaq. The broader S&P 500 slipped 2 points to 1720.
